Kazia Therapeutics Ltd

Research Kazia Therapeutics Ltd (KZIA) on Bullrun: market cap USD 165.23M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerKZIA
• ExchangeNASDAQ
• CountryAustralia
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 165.23M
• Financial periodQ4 2025
• RevenueUSD 42.00K
• Net income-USD 22.80M
• Free cash flow-USD 14.40M

Valuation Snapshot

latest market cap is USD 165.23M.

About Kazia Therapeutics Ltd

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma;

Frequently asked questions

What is Kazia Therapeutics Ltd's market cap?

Kazia Therapeutics Ltd's market capitalization is USD 165.23M.

What does Kazia Therapeutics Ltd do?

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel.